april operational update is out, page-4

solid update but slow & steady with the share price. the inherent risk of disease will keep a hand brake on sp appreciation. the company needs to perserve with the holy grail of sbt. i support continued investment in R&D within the company's means as if it comes to fruition then skys the limit. Still assuming continued progress with Kingfish the share price will be 10c+ in next 12 months.